EUVIMEDEUVIMED entdecken
Crossref

Lipid-lowering for the prevention of cardiovascular disease in the new era: A practical approach to combination therapy: Lipid-lowering and combination therapy

Erin D. Michos, Keith C. Ferdinand

European Atherosclerosis Journal · 2022

DOI: 10.56095/eaj.v1i1.9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Atherosclerosis Journal, 2022. Verfasst von Erin D. Michos und 1 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low density lipoprotein-cholesterol (LDL-C) is the main etiologic factor for the development and progression of atherosclerotic cardiovascular disease (ASCVD) and LDL-C reduction is a central tenet of ASCVD treatment and prevention. Moreover, ASCVD risk reduction is proportional to the magnitude of LDL-C lowering. Recent European guidelines have recommended a goal of

Zitieren

APA

Michos, E. D., & Ferdinand, K. C. (2022). Lipid-lowering for the prevention of cardiovascular disease in the new era: A practical approach to combination therapy: Lipid-lowering and combination therapy. European Atherosclerosis Journal. https://doi.org/10.56095/eaj.v1i1.9

Vancouver

Michos ED, Ferdinand KC. Lipid-lowering for the prevention of cardiovascular disease in the new era: A practical approach to combination therapy: Lipid-lowering and combination therapy. European Atherosclerosis Journal. 2022. doi:10.56095/eaj.v1i1.9

BibTeX
@article{Michos2022,
  author = {Michos, Erin D. and Ferdinand, Keith C.},
  title = {Lipid-lowering for the prevention of cardiovascular disease in the new era: A practical approach to combination therapy: Lipid-lowering and combination therapy},
  journal = {European Atherosclerosis Journal},
  year = {2022},
  doi = {10.56095/eaj.v1i1.9}
}
Kostenlos starten →